Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.75 |
| ▸ | RAB9A | P51151 | 1/20 | 0.75 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | NSD2 | O96028 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1208088 | 0.79 | SMN1; SMN2 (0.84) | GAASMN1; SMN2RAB9AL3MBTL1POLB | |
| SCHEMBL12584934 | 0.79 | SMN1; SMN2 (0.84) | GAASMN1; SMN2RAB9AL3MBTL1POLB | |
| SCHEMBL8790936 | 0.78 | SMN1; SMN2 (0.81) | GAASMN1; SMN2RAB9AL3MBTL1POLB | |
| SCHEMBL13932030 | 0.78 | SMN1; SMN2 (0.81) | GAASMN1; SMN2RAB9AL3MBTL1POLB | |
| SCHEMBL8791216 | 0.78 | SMN1; SMN2 (0.81) | GAASMN1; SMN2RAB9AL3MBTL1POLB | |
| SCHEMBL8791412 | 0.75 | RAB9A (0.75) | GAASMN1; SMN2RAB9AL3MBTL1POLB | |
| SCHEMBL1208101 | 0.74 | SMN1; SMN2 (0.72) | GAASMN1; SMN2RAB9AL3MBTL1POLB | |
| SCHEMBL14003534 | 0.74 | L3MBTL1 (1.00) | GAASMN1; SMN2RAB9AL3MBTL1POLB | |
| SCHEMBL14557477 | 0.72 | GAA (0.57) | GAASMN1; SMN2RAB9AL3MBTL1ALDH1A1 | |
| SCHEMBL9431536 | 0.70 | SMN1; SMN2 (0.55) | GAASMN1; SMN2RAB9AL3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037785-A1 | Novel dipeptidyl peptidase IV inhibitors used for functionally influencing different cells and treating immunological, infammatory, neuronal, and other diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2007-02-15 | — | — | US | disclosed |
| US-20070037785-A1 | Novel dipeptidyl peptidase IV inhibitors used for functionally influencing different cells and treating immunological, infammatory, neuronal, and other diseases | KEYNEUROTEK PHARMACEUTICALS AG (DE) | 2007-02-15 | — | — | US | disclosed |
| WO-2005037779-A2 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS USED FOR FUNCTIONALLY INFLUENCING DIFFERENT CELLS AND TREATING IMMUNOLOGICAL, INFLAMMATORY, NEURONAL, AND OTHER DISEASES | IMTM GMBH (DE) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037785-A1 | Novel dipeptidyl peptidase IV inhibitors used for functionally influencing different cells and treating immunological, infammatory, neuronal, and other diseases | DNPEP, PREP, DPP4 | GAA 108/4885SMN1; SMN2 4098/4885RAB9A 2391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.